Objectives

• Earn medical validation for an innovative new technology to detect esophageal pre-cancer
• Gather insights from leading gastroenterologists on clinical strategy and messaging

 Program

• Formed an advisory board consisting of top national gastroenterology thought-leaders and early adopters using the product
• Developed clinical strategy guidance documents and identified gaps in clinical data

Results

• Advisory board actually renamed the product
• Advisory board members designed a large multisite study that includes virtually every major esophageal cancer KOL
• Technology validation study requested by the advisory board was presented in an oral presentation at Digestive Disease Week (DDW), the largest gastroenterology medical meeting
• Large community-based study run by three members of the advisory board was presented in a Presidential Plenary session at DDW and other key conferences